Treats recurrent episodes. ANDA 202438, held by Hetero Labs Ltd V. Famciclovir.
As of Nov 16, 2026, ANDA 202438 (Famciclovir), held by Hetero Labs Ltd V, was first approved by FDA on Sep 10, 2014, with 2 approved supplements and 0 published complete response letters.
Famciclovir tablet, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2014 | Original application | Approved | None posted |
| Famciclovir125MG · tablet;oral | Famciclovir | Rx |
| Famciclovir250MG · tablet;oral | Famciclovir | Rx |
| Famciclovir500MG · tablet;oral | Famciclovir | Rx |
| Sep 3, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 3, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 10, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters